Moleculin Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Moleculin Biotech
MBRX Stock  USD 4.19  0.07  1.70%   
Moleculin Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Moleculin Biotech's valuation are provided below:
Market Capitalization
22.5 M
Earnings Share
(3.74)
We have found one hundred twenty available fundamental ratios for Moleculin Biotech, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Moleculin Biotech last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 35.8 M in 2026. Enterprise Value is likely to rise to about (22.7 M) in 2026
Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin Biotech's main balance sheet or income statement drivers, such as Interest Income of 912.6 K, Depreciation And Amortization of 223.7 K or Interest Expense of 2.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.93. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules.
  
Build AI portfolio with Moleculin Stock
Check out the analysis of Moleculin Biotech Correlation against competitors.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

Moleculin Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets33.7 M19.5 M21.2 M
Slightly volatile
Short and Long Term Debt Total421.4 K549.7 K414.3 K
Very volatile
Other Current Liabilities2.2 M3.7 M1.5 M
Slightly volatile
Total Current Liabilities3.9 M6.2 M2.9 M
Slightly volatile
Accounts Payable1.5 M2.3 M1.1 M
Slightly volatile
Cash4.7 M4.9 M11.6 M
Slightly volatile
Non Current Assets Total11.5 M13.5 M7.6 M
Slightly volatile
Cash And Short Term Investments4.7 M4.9 M11.6 M
Slightly volatile
Common Stock Total Equity83.3 K79.3 K38.6 K
Slightly volatile
Common Stock Shares Outstanding166.3 K158.4 K45.5 K
Slightly volatile
Liabilities And Stockholders Equity33.7 M19.5 M21.2 M
Slightly volatile
Non Current Liabilities Total3.2 M6.4 M2.4 M
Slightly volatile
Total Liabilities7.1 M12.6 M5.2 M
Slightly volatile
Short and Long Term Debt298.6 K266.8 K349 K
Slightly volatile
Total Current Assets5.7 M6 M12.6 M
Slightly volatile
Short Term Debt166.6 K108 K271 K
Slightly volatile
Common Stock3.3 K3.5 K18.7 K
Pretty Stable
Other Liabilities3.1 M1.6 M1.6 M
Slightly volatile
Property Plant And Equipment Net526.7 K670.5 K332.1 K
Slightly volatile
Capital Surpluse48.7 M85.9 M45.4 M
Slightly volatile
Other Current Assets1.7 M1.1 M1.1 M
Slightly volatile
Property Plant And Equipment Gross1.9 M1.8 M634.6 K
Slightly volatile
Intangible Assets12.3 M12.8 M11.3 M
Slightly volatile
Property Plant Equipment412.9 K511.8 K273.5 K
Slightly volatile
Net Invested Capital6.5 M6.9 M21.2 M
Pretty Stable
Net Receivables39.9 K23 K45 K
Slightly volatile
Capital Stock2.6 K2.7 K28 K
Slightly volatile
Capital Lease Obligations425 K549.7 K394.3 K
Slightly volatile
Non Current Liabilities Other220.8 K248.4 K271.1 K
Slightly volatile

Moleculin Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income912.6 K495 K886.1 K
Pretty Stable
Depreciation And Amortization223.7 K113.4 K705.4 K
Slightly volatile
Selling General Administrative7.1 M10.1 M5.2 M
Slightly volatile
Selling And Marketing Expenses5.9 M11.5 M6.6 M
Slightly volatile
Other Operating Expenses19.3 M30.6 M13.5 M
Slightly volatile
Research Development12.1 M20.4 M8.5 M
Slightly volatile
Total Operating Expenses19.3 M30.6 M13.5 M
Slightly volatile
Reconciled Depreciation141.5 K144.9 K84.8 K
Slightly volatile

Moleculin Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation115.4 K144.9 K80.4 K
Slightly volatile
Capital Expenditures11.1 K11.7 K74.5 K
Pretty Stable
End Period Cash Flow4.7 M4.9 M11.6 M
Slightly volatile
Stock Based Compensation1.7 M2 M1.2 M
Slightly volatile
Begin Period Cash Flow22.4 M27.1 M13.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.110.122.127
Slightly volatile
Payables Turnover0.08120.07730.0505
Slightly volatile
Cash Per Share33.9435.72347
Pretty Stable
Days Payables Outstanding4.6 K4.9 K12.6 K
Slightly volatile
Income Quality0.780.990.8398
Slightly volatile
Intangibles To Total Assets0.480.760.5437
Slightly volatile
Net Debt To EBITDA0.160.14331.0096
Slightly volatile
Current Ratio0.830.873.269
Slightly volatile
Capex Per Share0.10.115.543
Pretty Stable
Interest Debt Per Share3.793.9973.4825
Slightly volatile
Debt To Assets0.03090.03255.665
Slightly volatile
Days Of Payables Outstanding4.6 K4.9 K12.6 K
Slightly volatile
Ebt Per Ebit1.00.940.9449
Slightly volatile
Effective Tax Rate0.01360.01530.0167
Slightly volatile
Quick Ratio0.830.873.269
Slightly volatile
Net Income Per E B T0.780.880.965
Slightly volatile
Cash Ratio0.680.723.0382
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0218
Slightly volatile
Debt Ratio0.03090.03255.665
Slightly volatile

Moleculin Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap35.8 M45 M41.2 M
Slightly volatile

Moleculin Fundamental Market Drivers

Moleculin Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Moleculin Biotech Financial Statements

Moleculin Biotech investors use historical fundamental indicators, such as Moleculin Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.3 M1.4 M
Cost Of Revenue144.9 K142.7 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY